Veterinary Pain Management Drugs Market Size, Share, Treatment Trends, Segmentation and Forecast, 2026–2035

Veterinary Pain Management Market Size & Forecast 2035

The global veterinary pain management drugs market was valued at USD 2.26 billion in 2025 and is projected to reach USD 3.62 billion by 2035, growing at a CAGR of 4.8% during 2026–2035. The market covers prescription and authorized nonprescription medicines used to control acute, perioperative, inflammatory, neuropathic, cancer-related and musculoskeletal pain in companion animals and livestock. Included classes are nonsteroidal anti-inflammatory drugs, opioids, local anesthetics, alpha-2 agonists, anti-nerve-growth-factor monoclonal antibodies, disease-modifying osteoarthritis therapies and other veterinary analgesics. Supplements without a recognized pain-management claim, diagnostic services and physical-rehabilitation revenue are excluded.

Veterinary pain care is moving from episodic treatment toward longitudinal management. Aging dogs and cats, greater recognition of feline pain and earlier osteoarthritis assessment are expanding chronic-treatment opportunities. At the same time, perioperative protocols increasingly combine agents with different mechanisms to reduce reliance on any single drug. Commercial success depends on more than efficacy: dose convenience, species-specific evidence, safety monitoring, owner adherence, reimbursement or affordability and the clinic’s ability to recognize pain all influence use.

The fastest value creation is occurring where treatment addresses a clearly defined unmet need. Anti-NGF monoclonal antibodies established a recurring injectable category for canine and feline osteoarthritis. Conditional pathways are also enabling products for uncommon but serious disorders such as pain associated with Chiari-like malformation and syringomyelia. Generic NSAIDs increase price competition in mature indications, making differentiated mechanisms and clinic education increasingly important.

Key Highlights

• Market revenue rises from USD 2.26 billion in 2025 to USD 3.62 billion in 2035 at a 4.8% CAGR.
• NSAIDs held 46% of 2025 revenue because of their broad use in osteoarthritis and postoperative care.
• Companion animals generated 81% of sales, reflecting higher spending per patient and long-duration osteoarthritis treatment.
• Joint and osteoarthritis pain represented 48% of market demand, equal to USD 1.08 billion.
• Veterinary hospitals and clinics controlled 66% of distribution revenue because diagnosis, prescribing and injectable administration remain clinic-led.
• North America held 43% of the global market, with the United States accounting for 38%.
• Novel biologics and neuropathic-pain treatments are widening the market while generics pressure established NSAID pricing.

Clinical and Commercial Dynamics

Chronic osteoarthritis converts pain control into recurring care

Osteoarthritis is commonly underrecognized because owners may interpret reduced activity, difficulty climbing stairs or altered grooming as normal aging. Structured mobility questionnaires and orthopedic examinations create earlier treatment opportunities. Monthly clinic-administered biologics support persistence but require repeat visits, while oral medicines offer home convenience and require owner adherence. Successful protocols increasingly combine medication with weight management, controlled activity and rehabilitation.

Multimodal perioperative care raises protocol complexity

Surgical pain may involve NSAIDs, opioids, alpha-2 agonists, local blocks and extended-release local anesthetics. Combining mechanisms can improve comfort and reduce the dose burden of individual drugs, but it also increases the need for training, monitoring and clear contraindication rules. Hospitals value products that fit anesthesia workflows, provide predictable duration and allow smooth transition from clinic to home.

Biologics alter the competitive basis of canine and feline OA care

Anti-NGF monoclonal antibodies introduced a targeted mechanism and monthly administration for osteoarthritis pain. Their adoption creates a high-value category distinct from daily oral NSAIDs. Post-approval surveillance and transparent communication are central because treated animals are often elderly and have multiple conditions. Safety signals, label changes or owner perceptions can therefore influence utilization more quickly than in established generic categories.

Species-specific evidence remains a market barrier

Cats metabolize medicines differently from dogs, and livestock use must account for food residues and withdrawal periods. Products cannot be transferred casually across species or indications. Small addressable populations and difficult clinical endpoints can discourage development. Conditional approval and minor-use incentives may improve the economics for uncommon diseases and underserved species.

Affordability shapes persistence

Chronic pain treatment competes with diagnostics, food, parasiticides and management of other age-related diseases. Monthly injections and branded therapies can face discontinuation if owners do not observe a clear functional benefit. Practices that establish baseline mobility measures and schedule reassessment can make outcomes more visible. Generic approvals expand access but also compress mature product margins.

Recognition tools create demand before products do

Cats and prey species may conceal pain, while livestock signs can be subtle at herd level. Grimace scales, mobility checklists and staff education improve recognition and standardize reassessment. Companies investing in veterinarian education and owner communication can expand appropriate diagnosis without relying solely on direct product promotion.

Market Scope

Quantitative Market Segmentation

By Drug Type

Nonsteroidal anti-inflammatory drugs accounted for 46% of 2025 revenue, equal to USD 1.04 billion. Carprofen, meloxicam, deracoxib, firocoxib, robenacoxib and grapiprant-based products serve osteoarthritis and postoperative indications. Broad familiarity and oral dosing support use, while renal, hepatic and gastrointestinal considerations require patient selection and monitoring.

Biologics and disease-modifying osteoarthritis therapies held 18%, or USD 0.41 billion. The segment includes anti-NGF monoclonal antibodies and other differentiated joint-pain products. Recurring administration and premium pricing support value, while continued pharmacovigilance and clinic engagement influence adoption.

Opioids represented 13%, equal to USD 0.29 billion, concentrated in perioperative, trauma, cancer and severe-pain protocols. Controlled-substance requirements and efforts to reduce opioid exposure limit routine use. Local anesthetics contributed 10%, or USD 0.23 billion, including infiltration, nerve-block and extended-release approaches.

Alpha-2 agonists generated 7%, equal to USD 0.16 billion, primarily through sedation and perioperative analgesia. Other products, including gabapentinoids and specialized neuropathic-pain medicines, held 6%, or USD 0.14 billion.

By Route of Administration

Oral medicines represented 51% of 2025 revenue, equal to USD 1.15 billion. Tablets, chewables and oral liquids are central to home treatment and chronic osteoarthritis management. Parenteral products held 42%, or USD 0.95 billion, including clinic-administered biologics, injectable NSAIDs, opioids, alpha-2 agonists and local anesthetics. Topical and transdermal products accounted for 7%, equal to USD 0.16 billion, offering useful alternatives where oral administration is difficult.

By Animal Type

Companion animals generated 81% of the market, worth USD 1.83 billion. Dogs represented the largest patient and revenue pool because osteoarthritis diagnosis, orthopedic surgery and chronic treatment are well established. Cats form a smaller but expanding segment as feline-specific products and recognition tools improve pain identification.

Livestock accounted for 19%, or USD 0.43 billion. Pain management is used around surgery, lameness, injury, mastitis, dehorning, castration and other husbandry procedures. Economics per animal, food-residue rules, administration practicality and producer education influence treatment.

By Application

Joint pain and osteoarthritis led with 48% of 2025 revenue, equal to USD 1.08 billion. Postoperative pain represented 27%, or USD 0.61 billion, supported by soft-tissue, orthopedic and dental procedures. Cancer pain held 9%, equal to USD 0.20 billion. Neuropathic pain accounted for 6%, or USD 0.14 billion, while trauma, dental pain and other indications contributed 10%, equal to USD 0.23 billion.

By Distribution Channel

Veterinary hospitals and clinics controlled 66% of revenue, equal to USD 1.49 billion. Clinics diagnose the condition, initiate therapy and administer injectables. Retail and veterinary pharmacies held 21%, or USD 0.47 billion, while authorized online pharmacies represented 13%, equal to USD 0.29 billion. Online growth is strongest for repeat oral prescriptions, but prescription verification and counterfeit protection remain important.

Regional and Country-Level Analysis

North America

North America led with 43% of 2025 revenue, equal to USD 0.97 billion. The United States represented 38% of global sales, or USD 0.86 billion, supported by high companion-animal spending, specialist practices, insurance uptake and rapid adoption of branded therapies. Canada held 4%, equal to USD 0.09 billion, and Mexico contributed 1%, or USD 0.02 billion. FDA approvals and post-market safety communication strongly shape the regional category.

Europe

Europe held 29%, equal to USD 0.66 billion. The United Kingdom and Germany each represented 5% of global revenue, or USD 0.11 billion. France held 4%, equal to USD 0.09 billion, Italy contributed 3%, or USD 0.07 billion, and other European countries represented 12%, equal to USD 0.27 billion. Strong veterinary infrastructure and mature pet ownership support use, while national prescribing and pricing conditions create country variation.

Asia-Pacific

Asia-Pacific accounted for 18% of 2025 sales, equal to USD 0.41 billion, and offers the fastest growth outlook. Japan held 5% of the global market, or USD 0.11 billion, with an aging pet population and advanced clinics. China represented 4%, equal to USD 0.09 billion, Australia 3%, or USD 0.07 billion, India 2%, equal to USD 0.05 billion, and the rest of the region 4%, or USD 0.09 billion. Urban pet ownership and improved access to veterinary care support growth.

Latin America

Latin America represented 6%, equal to USD 0.14 billion. Brazil held 3% of global revenue, or USD 0.07 billion, while other countries contributed the remaining 3%. Companion-animal demand is expanding in major cities, but income differences and limited access to specialist care favor established NSAIDs and generic products.

Middle East and Africa

The Middle East and Africa held 4%, equal to USD 0.09 billion. Gulf companion-animal clinics and South Africa form key commercial centers, while livestock welfare and production medicine provide additional demand. Diagnostic access, medicine availability and veterinarian density limit broader use.

Competitive Landscape

Competition includes multinational animal-health companies, specialty veterinary pharmaceutical manufacturers and generic-drug suppliers. Branded portfolios benefit from clinical data, practitioner education and distributor access. Generic competition is strongest in mature NSAIDs, while biologics, extended-release products and uncommon indications offer differentiation.

Key participants include Zoetis Inc., Elanco Animal Health Incorporated, Boehringer Ingelheim Animal Health, Dechra Pharmaceuticals PLC, Merck Animal Health, Ceva Santé Animale, Vetoquinol S.A., Virbac, Norbrook Laboratories, Chanelle Pharma, Orion Corporation, TriviumVet and Cronus Pharma.

Detailed Company Profiles

Zoetis Inc.

Zoetis has reshaped companion-animal osteoarthritis treatment through Librela, a canine anti-NGF monoclonal antibody, and Solensia, a feline anti-NGF monoclonal antibody. Both are administered monthly by veterinary professionals and create recurring clinic-led therapy. The company also markets established pain products in regional portfolios. By June 2026, Zoetis reported that nearly 40 million Librela doses had been delivered globally. Its competitive position rests on biologics capability, a large field organization, veterinary education and pharmacovigilance. Continued safety monitoring and transparent benefit-risk communication remain material to category growth.

Elanco Animal Health

Elanco maintains a broad U.S. pain portfolio that includes Galliprant for canine osteoarthritis, Deramaxx, Onsior, Nocita, quellin and Zorbium. Galliprant is a prostaglandin EP4-receptor antagonist for canine OA pain and inflammation. Onsior provides robenacoxib formulations for canine and feline perioperative use, while Nocita is an extended-release local anesthetic and Zorbium offers transdermal buprenorphine for cats. This breadth allows Elanco to participate in chronic, perioperative and acute pain. Generic robenacoxib creates price pressure, increasing the importance of differentiated dosing and protocol support.

Dechra Pharmaceuticals

Dechra focuses on specialist veterinary pharmaceuticals and maintains anesthesia, sedation and analgesia products across multiple countries. Its portfolio includes products based on alpha-2 agonists, anesthetics and perioperative-support medicines, with availability varying by market. Dechra’s commercial model relies on veterinary-practice relationships and professional education. In September 2026, the company scheduled a two-part clinical program on alpha-2 agonists, sedation and perioperative pain management, reflecting its strategy of supporting product use through specialist-led training.

Boehringer Ingelheim Animal Health

Boehringer Ingelheim supplies companion-animal and livestock medicines and invests in external partnerships and internal R&D. Its pain-relevant portfolio varies by country and includes veterinary NSAIDs and products used within perioperative or inflammatory-disease care. The company’s scale in both livestock and companion animals provides access to diverse clinical settings. Its 2026 animal-health innovation outlook emphasized partnering in areas where new modalities and digital evidence can address unmet veterinary needs, including chronic disease and improved treatment delivery.

Recent Developments

• September 15 and 22, 2026 – Dechra: Dechra scheduled a two-part veterinarian program on alpha-2 agonists, sedation and perioperative pain management, translating current evidence into clinical protocol decisions.
• August 2026 – Zoetis: Zoetis updated its Librela scientific resources with global use data showing nearly 40 million doses delivered by June 2026 and additional discussion of post-approval musculoskeletal surveillance.
• June 30, 2026 – U.S. FDA: The FDA released its 2026–2028 Minor Use and Minor Species blueprint, outlining regulatory optimization, new market pathways, incentives and partnerships for underserved animal-drug indications.
• May 12, 2026 – U.S. FDA: The FDA conditionally approved TriviumVet’s Liavium-CA1, a pregabalin chewable tablet for pain and clinical signs associated with Chiari-like malformation and syringomyelia in dogs.
• May 2026 – Boehringer Ingelheim: The company published its 2026 animal-health partnering and innovation priorities, reinforcing external collaboration as a route to new veterinary therapies and delivery approaches.

Strategic Takeaways

• Prioritize chronic OA, neuropathic pain and species-specific unmet needs over crowded generic NSAID indications.
• Pair medicines with validated pain scales, mobility baselines and scheduled reassessment to demonstrate response.
• Build pharmacovigilance communication into commercialization for novel biologics and elderly patients.
• Design clinic workflows that support monthly injectables while preserving convenient home-treatment choices.
• Use multimodal protocol education to position portfolios across surgery, recovery and long-term care.
• Treat feline pain recognition and dosing convenience as separate development requirements from canine care.
• Protect access through tiered pricing, generics and owner-support programs without weakening veterinary oversight.